CARMIDO: Molecule repurposing in the treatment of obstructive cardiopathies


  • Treatment of severe, uncomfortable and incapacitating symptoms associated with obstructive cardiopathies
  • Global improvement of the quality of life of the patient
  • Human or veterinary purposes

The problem : Drug treatments such as beta-blockers or calcium channel blockers are moderately effective and sometimes associated with unacceptable side effects in hypertrophic cardiomyopathy patient


Pr Stéphane LAFITTE
Valvulopathy Medical & Surgical Service, University Hospital of Bordeaux


Nom : Christophe Zabawinski,
Titre : Chef de Projet Sciences de la Vie,
Mail :


  • Repurposing molecule improving symptoms associated with obstructive cardiopathies and especially hypertrophic cardiomyopathy:
    • exercise breathlessness
    • exercise chest pain
    • exercise discomfort
    • exercise dizziness
  • Validation with a first serie of human obstructive heart diseases
  • Reduction of symptoms at rest or during effort
  • Immediate decrease of intraventricular obstruction and hyperkinetic state
  • Ongoing phase II clinical study on 40 patients


  • Efficient treatment for reducing severe symptoms of patients suffering from obstructive cardiopathies
  • Large improvement in patients’ daily life
  • Safer approach compared to severe medications or invasive therapies currently used.


Patent application: WO 2017/021283 A1

By | 2018-01-22T18:14:21+00:00 juillet 20th, 2017|